Nyxol, an alpha 1/2 antagonist eye drop, helped reverse the effects of pharmacologically induced mydriasis in healthy subjects, according to a phase 3 study.
Jay S. Pepose, MD, PhD, told Ocular Surgery News that Nyxol (phentolamine mesylate ophthalmic solution 1%, Ocuphire) could present a unique treatment for patients following any of the 100 million yearly dilated eye exams in the United States every year.
“We know the impact on these patients in terms of glare and visual changes, and it’s problematic,” he said. “They want to get back to work (Read more...)